AMENDED WARNING LETTER CIN
|
|
- Meagan Chapman
- 6 years ago
- Views:
Transcription
1 Department of Health and Human Services Public Health Service Food and Drug Administration Cincinnati District Office Central Region 6751 Steger Drive Cincinnati, OH Telephone: (513) FAX: (513) August 13, 2012 Via United Parcel Services John Parrillo, Owner Parrillo Performance 6200 Union Center Boulevard Fairfield, Ohio Dear Mr. Parrillo: AMENDED WARNING LETTER CIN Between February 13, 2012 and February 29, 2012, the U.S. Food and Drug Administration (FDA) inspected your dietary supplement manufacturing and re-packaging facility located at 6200 Union Center Boulevard, Fairfield, Ohio The inspection revealed that you failed to comply with the Current Good Manufacturing Practice (CGMP) regulations for dietary supplements (21 CFR Part 111). These violations cause the dietary supplement products manufactured and packaged at your facility to be adulterated within the meaning of Section 402(g)(1) of the Federal Food, Drug and Cosmetic Act (the Act) [21 U.S.C. 342(g)(1)] in that they have been prepared, packed or held under conditions that do not meet the CGMP regulations for dietary supplements. You may find the Act and FDA regulations through links at FDA s home page at Our inspection of your facility revealed the following violations of the dietary supplement CGMP regulation (21 CFR Part 111): 1. You failed to establish component specifications that are necessary to ensure that specifications for the purity, strength, and composition of dietary supplements manufactured using the components are met, as required by 21 CFR (b). Specifically, you failed to establish component specifications for each component that you use in the manufacture of a dietary supplement. 2. Your firm failed to conduct at least one appropriate test or examination to verify the identity of a component that is a dietary ingredient, prior to its use, as required by 21 CFR 1
2 111.75(a)(1)(i). Specifically, your firm did not test or verify the identity of any dietary ingredients used in your products. Before using a component that is a dietary ingredient, you must conduct at least one appropriate test or examination to verify the identity of any component that is a dietary ingredient, unless you have petitioned FDA for an exemption from such testing, consistent with the requirements in 21 CFR (a)(1)(ii), and FDA has granted such petition. Your firm has not petitioned FDA for such an exemption. 3. Your firm failed to establish written procedures for the responsibilities of the quality control operations, including written procedures for conducting a material review and making a disposition decision, and for approving or rejecting any reprocessing, as required by 21 CFR Specifically, your firm does not have written procedures for quality control operations. 4. Your firm failed to prepare and follow a written master manufacturing record (MMR) for each unique formulation of dietary supplement that you manufacture, and for each batch size, to ensure uniformity in the finished batch from batch to batch, as required by 21 CFR (a). Specifically, you confirmed to our investigators that you do not prepare MMRs for any of your products. 5. Your firm failed to follow the requirements for batch production records (BPRs), as required by 21 CFR and Specifically, your BPRs did not include the following required information: A. The identity of equipment and processing lines used in producing the batch, as required by 21 CFR (b) B. The date and time of the maintenance, cleaning, and sanitizing of the equipment and processing batch, or a cross reference to records, such as individual equipment logs, where this information is retained, as required by 21 CFR (c) C. The unique identifier that you assigned to each component, packaging, and label used, as required by 21 CFR (d) D. Documentation that the finished dietary supplement meets specifications established in accordance with 21 CFR (e) and (g), as required by 21 CFR (i) E. Documentation at the time of performance, of the manufacture of the batch with the initials of the persons performing each step, including: a. The initials of the person responsible for weighing or measuring each component used in the batch; b. The initials of the person responsible for verifying the weight or measure of each component used in the batch; c. The initials of the person responsible for adding the component to the batch; d. The initials of the person responsible for verifying the addition of components to the batch. This documentation is required under 21 CFR (j)(2). 2
3 F. Documentation at the time of performance, of packaging and labeling operations, including: 1. The unique identifier that you assigned to packaging and labels used, the quantity of the packaging and labels used, and, when label reconciliation is required, reconciliation of any discrepancies between issuance and use of labels. 2. An actual or representative label, or cross-reference to the physical location of the actual or representative label specified in the MMR. This documentation is required under 21 CFR (k)(1)-(2). G. Documentation, at the time of performance, that quality control personnel: 1. Approved or rejected any reprocessing or repackaging; 2. Approved and released, or rejected, the batch for distribution including any reprocessed batch; 3. Approved and released, or rejected, the packaged and labeled dietary supplement, including any repackaged or relabeled dietary supplement. This documentation is required by 21 CFR (1). 6. Your firm failed to make and keep records to fulfill the requirements related to components, packaging, and labels, and for products received for packaging and labeling as a dietary supplement, as required by 21 CFR (a). Specifically, you have not made or kept receiving records for components, as required by 21 CFR (b)(2). 7. Your firm failed to establish and follow written procedures to fulfill the requirements related to product complaints, as required by 21 CFR Specifically, you have not established written procedures for the review and investigation of product complaints. In addition, your firm failed to make and keep the records of these procedures, as required by 21 CFR (b)(1). 8. Your firm failed to establish and follow written procedures to fulfill the requirements related to returned dietary supplements, as required by 21 CFR Specifically, you have not established written procedures that specify the procedures to be followed when a dietary supplement is returned by a customer. In addition, your firm failed to make and keep records of these procedures, as required by 21 CFR (b)(1). 9. Your firm failed to establish and follow written procedures for required steps in the manufacturing process. Specifically, you failed to establish written procedures for manufacturing operations, as required by 21 CFR In addition, your firm failed to make and keep records of these procedures, as required by 21 CFR (b). 3
4 10. Your firm failed to establish and follow written procedures to fulfill the requirements related to packaging and labeling operations, as required by 21 CFR Specifically, you have not established written procedures for packaging and labeling operations. In CFR (b). 11. Your firm failed to establish and follow written procedures to fulfill the requirements related to holding and distributing operations, as required by 21 CFR Specifically, you have not established written procedures for holding and distributing operations. In CFR (b)(1). 12. Your firm failed to follow numerous requirements related to personnel. Specifically, your firm failed to use hygienic practices to the extent necessary to protect against contamination, as required by 21 CFR (b)(2). Your firm also failed to ensure that personnel remove all jewelry that cannot be adequately sanitized during periods in which components or dietary supplements are manipulated by hand [21 CFR (b)(4)], and failed to ensure that personnel wear beard covers where appropriate [21 CFR (b)(5)]. Our investigators noted the following practices: A. An employee manufacturing Graham Cracker Energy Bars reached elbow deep into the mixing bowl, but only washed and sanitized their hands and wrists. B. A different employee reached into the same mixing bowl while wearing a diamond ring. C. Two male employees with facial hair were observed manufacturing without wearing beard nets. 13. Your firm failed to establish and follow written procedures to fulfill the requirements related to equipment and utensils, as required by 21 CFR Specifically, you failed to establish written procedures for calibrating instruments and controls, inspecting equipment, and cleaning and sanitizing equipment that you use in manufacturing a component or dietary supplement [21 CFR (a), 21 CFR (c)]. In addition, your firm failed to make and keep records of these procedures, as required by 21 CFR (b)(1). 14. Your firm failed to establish and follow written procedures to fulfill the requirements related to your physical plant and grounds, as required by 21 CFR Specifically, you failed to establish written procedures for cleaning the physical plant and for pest control. In CFR (b). We received your response to the FDA 483 on March 21, Although you state in your response that you are working to address all of FDA s concerns, you failed to provide detailed information and documentation that would assist us in evaluating whether you have implemented the necessary corrections. Therefore, your response is inadequate. 4
5 The above violations are not intended to be an all-inclusive list of the violations at your dietary supplement facility. You are responsible for ensuring that your products are in compliance with the applicable statutes and regulations administered by FDA. You should take prompt action to correct these violations. Failure to take appropriate corrective action may result in regulatory action, including seizure and/or injunction, without further notice. In addition to the above violations, we have the following comment: Your firm does not retain reserve samples for one year past the shelf life date (if shelf life dating is used), or for 2 years from the date of distribution of the last batch of dietary supplements associated with the reserve samples, for use in appropriate investigations, as required by 21 CFR (b). Specifically, you informed our investigator that you only hold reserve samples for six months from the date of manufacturing. You should respond in writing within 15 working days from your receipt of this letter. Your response should include each step taken or that will be taken to correct these violations and to prevent their recurrence. You should include in your response documentation that would assist us in evaluating your corrections. If you cannot complete all corrections before you respond, state the reason for the delay and when you will correct the remaining violations. Your response should be sent to: Food and Drug Administration, Attention: Allison C. Hunter, Compliance Officer, 6751 Steger Drive, Cincinnati, OH If you have questions regarding any issues cited in this letter, please contact Ms. Hunter at , Extension 2134 or at allison.hunter@fda.hhs.gov. Sincerely /s/ Paul J. Teitell District Director Cincinnati District Office 5
Bristol Myers Squibb Holdings Pharma., Ltd.
Bristol Myers Squibb Holdings Pharma., Ltd. Department of Health and Human Services Public Health Service Food and Drug Administration 466 Fernandez Juncos Avenue Puerta De Tierra San Juan, Puerto Rico
More informationPREVENT YOUR DIETARY SUPPLEMENT LABORATORY FROM BECOMING A COMPLIANCE RISK. Marian Boardley 2013
PREVENT YOUR DIETARY SUPPLEMENT LABORATORY FROM BECOMING A COMPLIANCE RISK Marian Boardley 2013 APPLICABLE GMP S: DIETARY SUPPLEMENT LABS Subparts for laboratory operations and testing, 21 CFR 111 D Equipment
More informationBE-595M Homework Assignment Due: 3/3/08
BE-595M Homework Assignment Due: 3/3/08 Attached is a Warning Letter issued to Applied Water Engineering, Inc., Salt Lake City, UT, for violations of the Quality System Regulations. The firm manufactures
More informationInspections, Compliance, Enforcement, and Criminal Investigations
Inspections, Compliance, Enforcement, and Criminal Investigations Husain, Mustafa M, M.D. 23-Jul-08 Department of Health and Human Services Public Health Service Food and Drug Administration Center for
More informationInspections, Compliance, Enforcement, and Criminal Investigations
1 of 5 2/11/2014 11:24 AM Home Inspections, Compliance, Enforcement, and Criminal Investigations Enforcement Actions Warning Letters Inspections, Compliance, Enforcement, and Criminal Investigations Baxter
More informationWARNING LETTER CERTIFIED MAIL -~ Q December 14, 2005
-~ Q DEPARTMENT Or HEALTI-I A\D HUMAN SERVICES Public Health Service Food and Drug Administration Central Region Telephone (973) 526-6006 New Jersey District Waterview Corporate Center 10 Waterview Blvd.,
More informationExecutive Summary 56,173 Purpose and Coverage of the Rule 56,173 Summary of the Major Provisions of the Rule 56,173 Costs and Benefits 56,175
Executive Summary 56,173 Purpose and Coverage of the Rule 56,173 Summary of the Major Provisions of the Rule 56,173 Costs and Benefits 56,175 I. Background 56,176 A. FDA Food Safety Modernization Act 56,176
More informationTexas Department of State Health Services
Texas Department of State Health Services DRUGS AND MEDICAL DEVICES GROUP WEB SITE: http://www.dshs.state.tx.us/dmd/ ISSUANCE OF CERTIFICATES OF FREE SALE AND SANITATION AND/OR CERTIFICATES OF ORIGIN AND
More information: study utilizing trieib)(4) b)(4) I I""-", _
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration 9200 Corporate Boulevard Rockville, Maryland 20850 WARNING LETTER VIA FEDERAL EXPRESS Sarah H. Lisanby, M.D. 1051
More informationSJN DO CB Field Alert Reports. Edwin Ramos Director of Compliance Food and Drug Administration San Juan District Office
SJN DO CB Field Alert Reports Edwin Ramos Director of Compliance Food and Drug Administration San Juan District Office SJN DO Mission Assuring that safe and effective drugs are available to the public
More informationGuidance for Industry
Guidance for Industry Self-Identification of Generic Drug Facilities, Sites, and Organizations DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions
More informationCenter for Drug Evaluation and Research - Compliance Central with FDA Center Compliance Directors: Part 1
Center for Drug Evaluation and Research - Compliance Central with FDA Center Compliance Directors: Part 1 Donald D. Ashley, JD 2017 FDLI Enforcement, Litigation, and Compliance Conference: For the Drug,
More informationSECTION HOSPITALS: OTHER HEALTH FACILITIES
SECTION.1400 - HOSPITALS: OTHER HEALTH FACILITIES 21 NCAC 46.1401 REGISTRATION AND PERMITS (a) Registration Required. All places providing services which embrace the practice of pharmacy shall register
More informationFDA's OMB supporting document for QSr recordkeeping, 7/20/01, page 1 of 7
FDA's OMB supporting document for QSr recordkeeping, 7/20/01, page 1 of 7 DISCLAIMER: This document was prepared by editing the converted PDF file supporting FDA's request to OMB for continuation of record
More informationThe U.S. Food and Drug Administration s Food Safety Modernization Act: Current & Future Requirements
The U.S. Food and Drug Administration s Food Safety Modernization Act: Current & Future Requirements Beatrice Moreau Senior Regulatory Advisor Registrar Corp 144 Research Drive Hampton, Virginia USA 23666
More informationWARNING LETTER. an both of which were sponsored by. (formerly ). The products
g5~5s c Public Health Service ' SLRV7CLS r r f+ ~1Mr~la DEPARTMENT OF HEALTH & HUMAN SERVICES DEC 2 1 2005 Food and Drug Administration 9200 Corporate Blvd. Rockville, Maryland 20850 WARNING LETTER Via
More informationWARNING LETTER VIA FEDERAL EXPRES S
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration 9200 Corporate Boulevard Rockville, Maryland 20850 WARNING LETTER VIA FEDERAL EPRES S George W. LeMaitre Chairman
More informationFDA Reportable Food Registry. David E. Gombas, Ph.D. United Fresh Produce Association September 21, 2009
FDA Reportable Food Registry David E. Gombas, Ph.D. United Fresh Produce Association September 21, 2009 Reportable Food Registry Part of the FDA Amendments Act Signed into law on September 27, 2007 Amends
More information:,-, WARNING LETTER. Mr. Jean Claude Mas Chief Executive Officer Poly Implants Protheses, Sa 337 Avenue De Bruxelles La Seyne, Sur Mer France
+., %- *: $1.,X,, *,+,,r + $, DEPARTMENT +, %, >,,, :,-, OF HEALTH & HUMAN SERVICES Public Health Service VIA FEDERAL EXPRESS ~ 22moo WARNING LETTER Mr. Jean Claude Mas Chief Executive Officer Poly Implants
More informationFDA s Office of Regulatory Affairs: Violation Trends & Medical Device Update
FDA s Office of Regulatory Affairs: Violation Trends & Medical Device Update Ginger M. Sykes Supervisory Consumer Safety Officer Salt Lake City Resident Post Office of Regulatory Affairs U.S. Food and
More informationGuidelines for Incubator Kitchens
Guidelines for Incubator Kitchens Association of Food and Drug Officials www.afdo.org September 2017 Table of Contents 1. Introduction... Page 3 2. Purpose... Page 3 3. History... Page 4 4. Definitions...
More informationAre You Ready for FSMA? Janet Raddatz VP Quality & Food Safety Systems Sargento Foods Inc. WAFP June 12, 2013
Are You Ready for FSMA? Janet Raddatz VP Quality & Food Safety Systems Sargento Foods Inc. WAFP June 12, 2013 New Responsibilities for Food Companies Impacting daily operations in all registered facilities,
More informationNSF Dietary Supplement Complete Service Offering. Experts in supplement auditing, consulting, testing and training.
NSF Dietary Supplement Complete Service Offering Experts in supplement auditing, consulting, testing and training www.nsf.org Dietary Supplement Quality Training NSF Dietary Supplement Quality Training
More informationAgency Information Collection Activities; Proposed Collection; Comment Request; Survey
This document is scheduled to be published in the Federal Register on 07/02/2018 and available online at https://federalregister.gov/d/2018-14158, and on FDsys.gov 4164-01-P DEPARTMENT OF HEALTH AND HUMAN
More informationVersion 1.1, 6/30/2016 Guidance for Abbreviated IDE Requirements
Version 1.1, 6/30/2016 Guidance for Abbreviated IDE Requirements The Principal Investigator of a study that is requesting an abbreviated IDE for use of a non-significant risk device must attest to the
More informationGuidance for Industry ANDA Submissions Prior Approval Supplements Under GDUFA
Guidance for Industry ANDA Submissions Prior Approval Supplements Under GDUFA DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this
More information950 t2.d Public Heallh Service
DEPARTMENT OF HEALTH & HUMAN SERVICES CERTIFIED MAIL RETURN RECEIPT REQUESTED 950 t2.d Public Heallh Service Food and Drug Administration Detroit District 300 River Place Suite 5900 Detroit, MI 48207 Telephone:
More informationMay 12, 2016 MEMORANDUM. Certain provisions of FSMA are already in effect, namely: Mandatory recall authority (FSMA 206).
L A W O F F I C E S 7 0 0 T H I R T E E N T H S T R E E T, N. W. S U I T E 1 2 0 0 W A S H I N G T O N, D. C. 2 0 0 0 5-5 9 2 9 ( 2 0 2 ) 7 3 7-5 6 0 0 F A C S I M I L E ( 2 0 2 ) 7 3 7-9 3 2 9 w w w.
More informationFSMA Update. Samantha Shinbaum. October 3, 2017
FSMA Update Samantha Shinbaum October 3, 2017 Background Information A Little About Me Received my Bachelors from the University of Florida. Received my Masters from the University of Arkansas. Working
More informationEstablishment Registration and Device Listing. Michelle C. Jackson, Esq. Partner Venable LLP
Establishment Registration and Device Listing Michelle C. Jackson, Esq. Partner Venable LLP Learning Objectives Statutory Basis for Registration and Listing Relevant Regulations Who Must Register and List
More informationSubmitted electronically via: May 20, 2015
Submitted electronically via: http://www.regulations.gov May 20, 2015 Jane Axelrad, JD Associate Director for Policy, CDER Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers
More informationComplaint Handling and Medical Device Reporting (MDRs)
Complaint Handling and Medical Device Reporting (MDRs) FDA Small Business Regulatory Education for Industry (REdI) Bethesda, MD September 26, 2013 Andrew Xiao Consumer Safety Officer, Postmarket and Consumer
More informationCompounded Sterile Preparations Pharmacy Content Outline May 2018
Compounded Sterile Preparations Pharmacy Content Outline May 2018 The following domains, tasks, and knowledge statements were identified and validated through a role delineation study. The proportion of
More informationThe City of Carson RESPIRATORY PROTECTION PROGRAM PLAN
The City of Carson RESPIRATORY PROTECTION PROGRAM PLAN Updated Page 2 of 8 I. INTRODUCTION As required by California Code of Regulations, Title 8, Section 5144, entitled Respiratory Protection, the city
More informationContains Nonbinding Recommendations
Establishing and Maintaining a List of U.S. Milk and Milk Product, Seafood, Infant Formula, and Formula for Young Children Manufacturers/Processors with Interest in Exporting to China: Guidance for Industry
More informationWIRBinar. How to Survive an FDA Inspection. Upcoming Trainings: Contact Us: (360)
WIRBinar How to Survive an FDA Inspection 10-26-2011 Brought to you by WIRB Education and Consulting Services. Improve your ability to maintain compliance and protect human subjects with guidance from
More informationChapter 21. FDA Inspections
Chapter 21 FDA Inspections Jennifer M. Thomas & Douglas B. Farquhar 21:1 Role of Inspections 21:1.1 Overview 21:1.2 FDA s Reasons to Inspect 21:1.3 Potential Outcomes of Inspections 21:2 FDA Authority
More informationDEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service 3%3&4
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service 3%3&4 JUL 1 3 2CG3 WARNING LETTER Food and Drug Administration Center for Devices and Radiological Health 2098 Gaither Road Rockville, MD 20850
More informationSUBSTITUTE FOR HOUSE BILL NO. 4271
HB-, As Passed House, December, 0 SUBSTITUTE FOR HOUSE BILL NO. A bill to regulate medical marihuana provisioning centers and other related entities; to provide for the powers and duties of certain state
More informationSTUDY INFORMATION POST-IRB APPROVAL FDA DEVICE (IDE) SPONSOR AND INVESTIGATOR RESPONSIBILITY (21 CFR 812)
POST-IRB APPROVAL FDA DEVICE (IDE) SPONSOR AND INVESTIGATOR RESPONSIBILITY (21 CFR 812) Purpose: Investigators who initiate and submit an IDE application to the FDA assume the responsibilities of both
More informationComplying with FSMA Food Defense Rule. Pest Invasion Premier Food Industry Pest Management Seminar. Dr. Craig Henry, Intro Inc.
Complying with FSMA Food Defense Rule Pest Invasion Premier Food Industry Pest Management Seminar Dr. Craig Henry, Intro Inc. April 2017 1 Key Topics 1. Things to Consider about Food Defense 2. Key Components
More informationSTATE OF FLORIDA DEPARTMENT OF HEALTH
DEPARTMENT OF HEALTH, STATE OF FLORIDA DEPARTMENT OF HEALTH PETITIONER, v. CASE NO. 2017-05245 SOUTHEAST COMPOUNDING PHARMACY, LLC, RESPON DENT. ADMINISTRATIVE COMPLAINT COMES NOW, Petitioner, Department
More informationDEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service
60-4 (v4 ( ~' DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service. Food and Drug Administration 9200 Corporate Boulevard el Rockville, Maryland 20850 MAY - 6 2008 VIA FEDERAL EXPRES S Merrill W.
More informationPersonal Hygiene. Author Date Dept. Approval Signature Date Q.A. Approval Signature Date
I. Purpose To prevent contamination of health supplement products by employees in the manufacturing area. I. Scope II. This standard operating procedure applies to employees who handle health supplement
More informationReceived an RTA Deficiency List or AI Letter? Now What?
Received an RTA Deficiency List or AI Letter? Now What? Dealing with Unexpected Issues/Questions during the Submission Review Process Navigating Submission Challenges to reduce time & risk September 26,
More information2015 Annual FDA Medical Device Quality System Data. Inspections, FDA Form 483 Observations, and Warning Letter Citations
2015 Annual FDA Medical Device Quality System Data Inspections, FDA Form 483 Observations, and Warning Letter Citations Why is FDA making these data available? In support of the FDA s Transparency and
More informationFSMA User Guide. Food Safety Modernization Act Guide
Food Safety Modernization Act Guide The Food Safety Modernization Act of 2011 (FSMA), the first major overhaul of food safety legislation in more than 70 years, gives FDA the new job of building a modern,
More informationSFHPHARM11 - SQA Unit Code FA2X 04 Prepare extemporaneous medicines for individual use
Prepare extemporaneous medicines for individual use Overview This standard covers your role in preparing extemporaneous medicines for individual use. This involves accurately calculating the quantities
More informationPharmaceutical Services Requirements: formerly 10D and 10C.7
Pharmaceutical Services Requirements: formerly 10D.28-29 and 10C.7 Frank S. Emanuel, Pharm.D., FASHP Associate Professor/Division Director Florida A and M University College of Pharmacy Jacksonville Disclosure
More informationComplaints Investigation and Review. Dr. Ademola Daramola International Relations Specialist Drugs US FDA India Office New Delhi February 22nd 2018
Complaints Investigation and Review Dr. Ademola Daramola International Relations Specialist Drugs US FDA India Office New Delhi February 22nd 2018 Information presented in this presentation does not represent
More informationSpecific Comments on Proposed Amendments
June 8, 2015 Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane Room 1061 Rockville, MD 20852 RE: Docket No. FDA 2002-N-0323 Proposed Rulemaking: Amendments to Registration
More information+.,m 7. yw ~ ~ & DEC FEDERAL EXPRESS
+,*,s WC, ~ *4+ S* DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service, % %,+ 747 +,m 7 Food and Drug Administration 5 Jg FEDERAL EXPRESS 2088 Gaither Road Rockville MD 20850 yw ~ ~ & 4 DEC 21997
More informationFSMA Implementation FDA s Preventive Controls Rules
FSMA Implementation FDA s Preventive Controls Rules 2016 National Association of Dairy Regulatory Officials Annual Meeting July 11, 2016 CAPT Robert (Bob) Hennes, MST Leader Presentation Overview FSMA
More informationCLINICAL LABORATORY IMPROVEMENT AMENDMENTS OF 1988: HOW TO ASSURE QUALITY LABORATORY SERVICES
CLINICAL LABORATORY IMPROVEMENT AMENDMENTS OF 1988: HOW TO ASSURE QUALITY LABORATORY SERVICES OVERVIEW In response to public health concerns over largely unregulated laboratory services, Congress enacted
More informationPersonal Protective Equipment Program. Risk Management Services
Personal Protective Equipment Program Services Table of Contents I. Program Goals and Objectives... 2 II. Scope and Application... 2 III. Responsibilities... 2 IV. Procedures... 3 V. Training... 5 VI.
More informationTO BE RESCINDED Home-delivered meal service.
ACTION: Final DATE: 08/22/2016 9:11 AM TO BE RESCINDED 173-39-02.14 Home-delivered meal service. (A) "Home-delivered meal service" means the service that provides up to two meals per day to a consumer
More informationAdministration OCCUPATIONAL HEALTH AND SAFETY
ACCREDITATION STANDA RDS OCCUPATIONAL HEALTH AND SAFETY The accreditation standards relating to occupational health and safety include those most critical to staff safety in the non-hospital setting; however,
More informationINTRODUCTION TO HACCP
INTRODUCTION TO HACCP NINA G. PARKINSON NGP CONSULTING NOVEMBER 12, 2014 NGP Consulting Nov 2014 1 COMMENTS FROM 2013 Waaay too much information! Didn t even get to the end with FSMA stuff! Basic, but
More informationChanges to QSR. The table below provides a history of changes to FDA s Quality System Regulation (QSR)
Changes to QSR The table below provides a history of changes to FDA s Quality System Regulation (QSR) The citation is to the Federal R: the first number is the volume, FR indicates the Federal Register,
More informationPrerequisite Program D: Personnel
Prerequisite Program D: Personnel Hand Washing 2 Good Personal Hygiene - Personnel 3 Good Personal Hygiene - Visitors 3 Illness and Injury 3 Health & Hygiene Training Records 3 Equipment Operation: Labeler
More informationInspections, Compliance, Enforcement, and Criminal Investigations
Inspections, Compliance, Enforcement, and Criminal Investigations Dallas Jr, Anthony V, MD 11/09/09 Department of Health and Human Services Public Health Service Food and Drug Administration Silver Spring,
More information5.1 EXAMPLES ON HOW TO LABEL
5 PART 5: LABELLING Note: The label sizes in the examples in Section 5.1.3 are not illustrated in the actual size but are only examples of possible lay-outs. The print quality is also not the same as when
More informationRespiratory Protection Program
Respiratory Protection Program Office of Environmental Health and Safety Revised July, 2012 Cleveland State University Respiratory Protection Program 1 Cleveland State University Respiratory Protection
More informationFDA HAS MADE PROGRESS
Department of Health and Human Services OFFICE OF INSPECTOR GENERAL FDA HAS MADE PROGRESS ON OVERSIGHT AND INSPECTIONS OF MANUFACTURERS OF GENERIC DRUGS Daniel R. Levinson Inspector General May 2015 OEI-01-13-00600
More informationWho Is OSHA? Who Is PERRP?
Who Is OSHA? Who Is PERRP? Occupational Safety and Health Administration Public Employment Risk Reduction Program Both agencies are responsible for worker safety and health protection. 2 PERRP History
More informationEHR] A INSPECTION REPORT. Guy s Hospital Pharmacy St Thomas Street London SE1 9RT. Safeguarding public health
Safeguarding public health EHR] A INSPECTION REPORT Guy s Hospital Pharmacy St Thomas Street London SE1 9RT Head Office: Inspection & Standards Division, Market Towers, I Nine Elms Lane, Vauxhall, London,
More informationTHE ALMOND FOOD SAFETY PLAN: TEACHING EXAMPLE FOR FSMA PREVENTIVE CONTROLS. Room 314 December
THE ALMOND FOOD SAFETY PLAN: TEACHING EXAMPLE FOR FSMA PREVENTIVE CONTROLS Room 314 December 5 2017 CEUs New Process Certified Crop Advisor (CCA) Sign in and out of each session you attend. Pickup verification
More informationDEPARTMENT OF HEALTH & Hl'NIAfV SERVICES Public Hcaffh Scn-ice WARNING LETTER
DEPARTMENT OF HEALTH & Hl'NIAfV SERVICES Public Hcaffh Scn-ice Food and Drug Administration 9200 CCorporate Bl%d. RockOlc MD 20550 WARNING LETTER VIA FEDERAL EXPRESS MP 4 2007 William D. Tobler, MD Mayfield
More informationHealth Care Dining Service
Health Care Dining Service A Workbook for Employee Training Level I Written by Wayne Toczek Edited,and formatted by Ari Sutton A Product of Innovations Services 102 Parsons St. Norwalk, OH 44857 419-663-9300
More informationInvestigator Roles and Responsibilities in Clinical Device Trials
Investigator Roles and Responsibilities in Clinical Device Trials A Total Product Lifecycle Approach to Medical Device Development: Responsibilities and Opportunities The Stanford Center for Clinical and
More information. s%rwcu ~,+ *+ % %vd3a 7 Food and Drug Administration. Center for Devices and
* %. s%rwcu ~,+ *+ Jf ~ DEPARTMENT OF HEAITH & HUMAN SERVICIB Public Health Setvice z 2 4/5924 % % %vd3a 7 Food and Drug Administration. Center for Devices and Radiological 2098 Gaither Road Via Federal
More informationMedical Device Reporting for Manufacturers
Medical Device Reporting for Manufacturers DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Food and Drug Administration Medical Device Reporting for Manufacturers Prepared by Division of
More informationFDA Reauthorization Act of 2017 (FDARA)
FDA Reauthorization Act of 2017 (FDARA) April 4, 2018 PRESENTED BY: Jessica Ringel Counsel FDA & Life Sciences Practice Group King & Spalding LLP (202) 626-9259 jringel@kslaw.com FDA Reauthorization Act
More informationLCDR Kemi Asante, PharmD, RAC Health Science Policy Analyst Office of Prescription Drug Promotion CDER FDA
Providing Regulatory Submissions in Electronic and Non-Electronic Format Promotional Labeling and Advertising Materials for Human Prescription Drugs Draft Guidance for Industry LCDR Kemi Asante, PharmD,
More informationSeptember 1, Comments on Draft Reportable Food Registry (RFR) Guidance; Docket No. FDA-2009-D-0260
Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane Room 1061 Rockville, Maryland 20852 Re: Comments on Draft Reportable Food Registry (RFR) Guidance; Docket No. FDA-2009-D-0260
More informationFEMA Mission Statement and Critical Objectives MISSION STATEMENT: CRITICAL OBJECTIVES: Science. Advocacy. Communication
FEMA 2017-2018 Mission Statement and Critical Objectives MISSION STATEMENT: The Flavor and Extract Manufacturers Association furthers the business interests of its members through a sound scientific program
More informationConnie Hoy October 2013
Connie Hoy October 2013 Warning letter issued to firm for complaint handling Failure to report within 30 days Failure to implement adequate procedures Failure to establish standard review process No procedure
More informationChapter 48 - Bioresearch Monitoring
COMPLIANCE GUIDANCE MANUAL Chapter 48 - Bioresearch Monitoring Subject SPONSORS, CONTRACT RESEARCH ORGANIZATIONS AND MONITORS Implementation Date February 21, 2001 Completion Date Continuing Product Codes
More informationAgency Information Collection Activities; Proposed Collection; Comment Request; Survey on
This document is scheduled to be published in the Federal Register on 02/07/2018 and available online at https://federalregister.gov/d/2018-02413, and on FDsys.gov 4164-01-P DEPARTMENT OF HEALTH AND HUMAN
More informationSession 3 FDA Audits and Findings
Session 3 FDA Audits and Findings Byungja Marciante, Investigator US Food and Drug Administration Shanghai Centre-Suite 723 1376 Nanjing Xi Lu Shanghai, PRC 200040 美国食品药品管理局上海商城 723 室南京西路 1376 号中国上海 200040
More informationChapter 2 Management and Personnel
Chapter 2 Management and Personnel Parts 2-1 Supervision 2-2 Employee Health 2-3 Personal Cleanliness 2-4 Hygienic Practices 2-1 Supervision Subparts 2-101 Assignment 2-102 Demonstration 2-103 Food Protection
More informationFDA Food Safety Modernization Act FDA Proposed Rules & OTA Draft Comments
FDA Food Safety Modernization Act FDA Proposed Rules & OTA Draft Comments Laura Batcha Executive Vice President Gwendolyn Wyard Regulatory Director, Organic Standards & Food Safety OTA Webinar October
More informationAn Update on FDA s Good Laboratory Practice (GLP) for Nonclinical Laboratory Studies Proposed Rule
An Update on FDA s Good Laboratory Practice (GLP) for Nonclinical Laboratory Studies Proposed Rule SOT: Regulatory and Safety Evaluation Specialty Section Webinar September 29, 2017 Mark Seaton, Ph.D.,
More informationRespiratory Protection Plan
Respiratory Protection Plan Contents: Sample Respiratory Protection Plan Introduction... ii Plan Cover Sheet... 1 Policy... 2 Responsibility... 2 Plan Elements... 3 Organizational Responsibility Chart...
More informationGAO MEDICAL DEVICES. Status of FDA s Program for Inspections by Accredited Organizations. Report to Congressional Committees
GAO United States Government Accountability Office Report to Congressional Committees January 2007 MEDICAL DEVICES Status of FDA s Program for Inspections by Accredited Organizations GAO-07-157 Accountability
More informationControlling Office: Director of Clinical Services Effective Date: May 1, Applies to CAMTS: n/a Last Review: January 1, 2018
Statement of Policy Respiratory Program Policy #: SMS-022 Controlling Office: Director of Clinical Services Effective Date: May 1, 2013 Applies to CAMTS: n/a Last Review: January 1, 2018 Policy About 32
More informationOrganizations in Nuclear Medicine Part IV- Others of Importance. Bennett S. Greenspan, MD SNM MWM Orlando, FL January 27, 2012
Organizations in Nuclear Medicine Part IV- Others of Importance Bennett S. Greenspan, MD SNM MWM Orlando, FL January 27, 2012 Organizations in NM What Are They? What Do They Do? Why Should I Care? How
More information2016 Plan of Correction Data 1
2016 Plan of Correction Data 1 Retail Data Calendar Year 2015 2016 Number of Inspections 1263 1694 number of Plan of Correction s (POC s) issued 502 523 Regulatory Citations 2 & 2015 2016 number of POC
More informationRULES OF THE TENNESSEE BOARD OF PHARMACY CHAPTER STERILE PRODUCT PREPARATION IN PHARMACY PRACTICE TABLE OF CONTENTS
RULES OF THE TENNESSEE BOARD OF PHARMACY CHAPTER 1140-07 STERILE PRODUCT PREPARATION IN PHARMACY PRACTICE TABLE OF CONTENTS 1140-07-.01 Applicability 1140-07-.05 Labeling 1140-07-.02 Standards 1140-07-.06
More informationGUIDELINES ON PROCEDURAL ASPECTS FOR APPLICATIONS FOR MARKETING AUTHORIZATION OF MEDICINAL PRODUCTS
Doc. No. TFDA/DMC/MCER/---- TANZANIA FOOD AND DRUGS AUTHORITY GUIDELINES ON PROCEDURAL ASPECTS FOR APPLICATIONS FOR MARKETING AUTHORIZATION OF MEDICINAL PRODUCTS (Made under Section 52 (1) of the Tanzania
More informationDepartment of Defense INSTRUCTION
Department of Defense INSTRUCTION SUBJECT: DoD Hazard Communication (HAZCOM) Program NUMBER 6050.05 August 15, 2006 Incorporating Change 1, August 25, 2008 USD(AT&L) References: (a) DoD Instruction 6050.5,
More informationAgency Information Collection Activities; Submission for Office of Management and Budget
This document is scheduled to be published in the Federal Register on 05/25/2017 and available online at https://federalregister.gov/d/2017-10712, and on FDsys.gov 4164-01-P DEPARTMENT OF HEALTH AND HUMAN
More informationUSE AND DISCLOSURE OF PROTECTED HEALTH INFORMATION WITHOUT AUTHORIZATION
USE AND DISCLOSURE OF PROTECTED HEALTH INFORMATION WITHOUT AUTHORIZATION Policy The Health Science Center may disclose protected health information without a patient authorization in the following circumstances:
More informationCh. 129 NUCLEAR MEDICINE SERVICES CHAPTER 129. NUCLEAR MEDICINE SERVICES GENERAL PROVISIONS
Ch. 129 NUCLEAR MEDICINE SERVICES 28 129.1 CHAPTER 129. NUCLEAR MEDICINE SERVICES GENERAL PROVISIONS Sec. 129.1. Principle. 129.2. Organizational options. 129.3. Organization and staffing. 129.4. Director.
More informationTHE PREVENTIVE CONTROLS RULES AND THE FSPCA
THE PREVENTIVE CONTROLS RULES AND THE FSPCA Dr. Robert Brackett, Illinois Institute of Technology International Citrus & Beverage Conference Clearwater Beach, FL September 17, 2015 Food Safety Modernization
More informationMedical Device Reporting. FD&C Act CFR Direct Final Rule 2/28/05. As amended by:
Medical Device Reporting Direct Final Rule 2/28/05 FD&C Act 519 As amended by: Safe Medical Devices Act of 1990 Medical Device Amendments of 1992 FDA Modernization Act of 1997 Authority to require manufacturers,
More informationFDA Inspectional Process in Clinical Research An FDA Perspective. Annette Melendez, MPHsN Investigator Office of Biological Products Operations
FDA Inspectional Process in Clinical Research An FDA Perspective Annette Melendez, MPHsN Investigator Office of Biological Products Operations Outline BIMO PROGRAM OVERVIEW PROGRAM COVERED AREAS INSPECTIONAL
More informationObserver Report (F10 A) For the Hospitality Industry
Instructions to the Student Please provide this report to someone at your workplace, preferably a supervisor or team leader, who has observed you working with food over a period of time. This report contains
More informationUNIFORM AND DRESS CODE POLICY - BANK MEMBERS
UNIFORM AND DRESS CODE POLICY - BANK MEMBERS Introduction This Policy applies to all Bank Members and sets out NHSP s expectations in relation to dress and appearance whilst working shifts. It also provides
More informationDraft 11/3/2017. Crosswalk - Requirements for Foodborne Illness Training Programs Based on Standard 5
Draft 11/3/2017 Crosswalk - Requirements for Training Programs Based on Standard 5 Introduction: The 2012 2014 Interdisciplinary Training Committee (IFITC) obtained the Food Safety and Modernization Act
More information